MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
XOMA Corporation DSO Ratio 2011-2025 | XOMA
Annual DSO Ratio XOMA Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.26 | 22.2 | 58.3 | 101 | 2.75 | 37.1 | 26.8 | 64 | 38.9 | 89.1 | 77.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 101 | 2.26 | 47.3 |
Quarterly DSO Ratio XOMA Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.3 | 25.6 | 21.2 | - | 9.96 | - | - | - | 51.9 | 25 | 0.73 | - | 1.62 | 1.16 | 3.44 | - | 25.7 | 4.66 | 41.7 | 0.87 | 43.1 | 54 | 181 | 726 | 32.8 | 253 | 23.7 | 79.5 | 150 | 59.4 | 184 | 6.76 | 1 | 3.33 | 169 | 98.6 | 81.3 | 117 | 53.4 | 7.71 | 179 | 146 | 127 | 69.5 | 58.8 | 50.5 | 94.9 | 27.5 | 54.7 | 48.2 | 58.1 | 102 | 104 | 81.2 | 95.2 | 114 | 69.3 | 68.1 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 726 | 0.73 | 79.1 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
267 | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 212.3 | 5.5 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.4 | 1.49 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Aytu BioScience
AYTU
|
150 | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
134 | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Biogen
BIIB
|
57.9 | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.29 | -5.01 % | $ 631 M |  Israel |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
81.9 | $ 51.05 | -0.32 % | $ 103 B | USA |
 |
Abeona Therapeutics
ABEO
|
387 | $ 5.5 | 0.46 % | $ 118 M | USA |
 |
ADiTx Therapeutics
ADTX
|
621 | $ 2.36 | -7.29 % | $ 31.1 K | USA |
 |
BioXcel Therapeutics
BTAI
|
16.3 | $ 2.1 | -4.34 % | $ 5.32 M | USA |
 |
Coherus BioSciences
CHRS
|
263 | $ 1.42 | 6.77 % | $ 134 M | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Baudax Bio
BXRX
|
126 | - | 0.59 % | $ 63 K | USA |